genotype, physician prescribing pattern, and risk for long QT on serotonin selective reuptake inhibitors.

Pharmacogenomics 2019 04 15;20(5):343-351. Epub 2019 Apr 15.

Department of Neuropsychology, Sanford Health, Fargo, ND 58122, USA.

To examine the impact of  genotype on selective serotonin reuptake inhibitor (SSRI) prescribing patterns. : Observational cohort containing 507 unique individuals receiving an SSRI prescription with genotype already in their electronic medical record. Genotype was distributed as follows: n = 360 (71%) had no loss of function alleles, 136 (26.8%) had one loss of function allele and 11 (2.2%) had two loss of function alleles. For poor metabolizers exposed to sertraline, citalopram or escitalopram, providers changed prescribing patterns in response to alerts in the electronic medical record by either changing the drug, changing the dose or monitoring serial EKGs longitudinally. For intermediate metabolizers exposed to sertraline, citalopram or escitalopram, no alert was needed (mean QTc = 440.338 ms [SD = 31.1273] for , mean QTc = 440.371 ms [SD = 29.2706] for ; p = 0.995).

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562837PMC
April 2019
4 Reads

Publication Analysis

Top Keywords

loss function
12
function alleles
8
medical record
8
citalopram escitalopram
8
electronic medical
8
exposed sertraline
8
sertraline citalopram
8
metabolizers exposed
8
patterns response
4
genotype electronic
4
prescribing patterns
4
changed prescribing
4
cohort 507
4
prescription genotype
4
record changing
4
response alerts
4
receiving ssri
4
alerts electronic
4
ssri prescription
4
unique individuals
4

Similar Publications